AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03146247 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
Description: All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
Study NCT04170309 — intervention group
Intervention type: DRUG
Intervention: Ceftobiprole medocaril
Description: Participants in whom treatment with Ceftobiprole medocaril has been completed
Study NCT03004300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid maxillary expansion
Description: Device
Study NCT03004300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Description: Device
Study NCT03004300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Surgery
Study NCT03649048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Cisplatin
Description: Intravenous administration of High-Dose Cisplatin
Study NCT03649048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Cisplatin
Description: Intravenous administration of Low-Dose Cisplatin
Study NCT03649048 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Participating centres are to follow their local radiation treatment planning and delivery techniques.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT without Personalization
Description: Intervention involves a video describing CBT without a message about personalization.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT with Personalization
Description: Intervention involves a video describing CBT with a message about personalization.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADM without Personalization
Description: Intervention involves a video describing antidepressant medication without a message about personalization.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADM with Personalization
Description: Intervention involves a video describing antidepressant medication with a message about personalization.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Treatment without Personalization
Description: Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
Study NCT04639765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Treatment with Personalization
Description: Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
Study NCT03169348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir daclatasvir
Description: oral tablets
Study NCT03169348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir
Description: oral tablets
Study NCT03038737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bre.flex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.
Study NCT03038737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study NCT01975207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants will be treated as per clinic's standard treatment for depression.
Study NCT01975207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice
Study NCT01975207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Treatment Pathway
Description: There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family.
Study NCT01284205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterial Cell-Wall DNA Complex
Description: 8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
Study NCT01284205 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin
Description: mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
Study NCT01568476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal
Description: Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
Study NCT01568476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interneural
Description: Sciatic nerve blockade at the site of bifurcation
Study NCT00759928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg once daily by mouth
Study NCT00759928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice daily by mouth
Study NCT04470791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F(ab)2 antivenom therapy (antivipmyn®).
Description: Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
Study NCT04470791 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: F(ab)2 antivenom therapy (antivipmyn®).
Description: Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
Study NCT04470791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local cryotherapy.
Description: Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
Study NCT01771965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB Intervention
Description: The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
Study NCT00950625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: 200 mg of intraperitoneal lignocaine will be given once during surgery
Study NCT00950625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupevacaine
Description: 100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
Study NCT03895684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-2577 Seclidemstat
Description: Dose escalation and dose expansion of SP-2577.
Study NCT04190693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IMCY-0098 or placebo
Description: Long-term follow-up
Study NCT04190693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098 or placebo
Description: Long-term follow-up
Study NCT01452451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HM11260C
Description: 1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
Study NCT01452451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
Study NCT01781598 — intervention group
Intervention type: DEVICE
Intervention: Total knee arthroplasty (TKA) (Smith &Nephew®)
Study NCT04283084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Balance and Coordination Exercises
Description: With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
Study NCT02780687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT02629757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-elemene
Description: β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
Study NCT02768064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: temporary pacemaker insertion
Description: Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
Study NCT02768064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: temporary pacemaker insertion
Description: Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
Study NCT04343066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant insertion
Description: In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis.
Study NCT04012632 — intervention group
Intervention type: OTHER
Intervention: this study was an observational study and no interventions were given to the participants
Description: the participants were recruited and the data as well as blood sample were collected.
Study NCT04285749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin PO 80mg QD for 2 weeks
Study NCT04285749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA-sequencing
Description: RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
Study NCT04285749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene expression profiling
Description: Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
Study NCT03729297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
Study NCT02392897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Eating Frequency
Description: Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
Study NCT02392897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Eating Frequency
Description: Free-living participants will complete a 21-day low eating frequency (low EF) Phase
Study NCT05589415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition Transcranial Direct Current Stimulation
Description: High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps.
Study NCT05589415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transcranial Direct Current Stimulation
Description: Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
Study NCT04549584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vimentin/pan CK stain
Description: Vimentin/pan CK stain positive/negative
Study NCT00540501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.
Study NCT00540501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir and Intravenous Zanamivir
Description: Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.
Study NCT01631565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early allocation to palliative care
Description: Symptoms management (e.g. Pain, nausea, dehydration management).
Study NCT01631565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional status evaluation and dietary supplementation according to the patient requirements.
Study NCT01631565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation.
Description: Patient and care-taker psychoeducation, depression and anxiety evaluation.
Study NCT02576249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 4cc 0.5% ropivacaine
Study NCT02576249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 4cc of sterile normal saline (0.9%)
Study NCT02576249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1cc 40mg methylprednisolone
Study NCT02576249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1cc 40mg methylprednisolone
Study NCT01284439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxypropylmethylcellulose
Description: TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
Study NCT01284439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: QID to every 2 hous, 1-2 drops per each time, duration 1 month
Study NCT00242866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150
Study NCT00242866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW274150
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150
Study NCT00242866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match GW274150
Study NCT00242866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match GW274150
Study NCT03533465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complicated Grief Therapy (CGT)
Description: CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
Study NCT03157622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in vivo
Description: 10 sessions based on an individualized fear hierarchy
Study NCT03157622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Psychotherapy
Description: graded activity, relaxation techniques and cognitive interventions
Study NCT03633890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaZhu Rhodiola Rosea Capsule
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Study NCT03633890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DaZhu Rhodiola Rosea Simulation Capsule
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Study NCT00090857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT00090857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02122796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
Study NCT01551095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEGJ tube
Description: The self-propelled PEGJ feeding tube
Study NCT01739790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 1800 mg twice daily for 8 weeks
Study NCT01739790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
Study NCT01719406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, behavioral lifestyle education
Description: Twenty interactive weekly sessions that are scripted curriculum and peer led.
Study NCT00193037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin
Study NCT00193037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel